206 related articles for article (PubMed ID: 23911931)
1. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
2. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
Huang Y; Rizzo RC
Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
[TBL] [Abstract][Full Text] [Related]
3. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
[TBL] [Abstract][Full Text] [Related]
5. Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation.
Ahmed M; Sadek MM; Serrya RA; Kafafy AH; Abouzid KA; Wang F
J Mol Graph Model; 2013 Mar; 40():91-8. PubMed ID: 23353584
[TBL] [Abstract][Full Text] [Related]
6. A possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitors.
Tsou YA; Chen KC; Chang SS; Wen YR; Chen CY
J Biomol Struct Dyn; 2013 Dec; 31(12):1358-69. PubMed ID: 23140436
[TBL] [Abstract][Full Text] [Related]
7. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
Awale M; Mohan CG
J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
[TBL] [Abstract][Full Text] [Related]
9. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
10. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
Yu X; Wang T; Lou Y; Li Y
Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
[TBL] [Abstract][Full Text] [Related]
11. EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents.
Guda R; Kumar G; Korra R; Balaji S; Dayakar G; Palabindela R; Myadaraveni P; Yellu NR; Kasula M
J Photochem Photobiol B; 2017 Nov; 176():69-80. PubMed ID: 28964888
[TBL] [Abstract][Full Text] [Related]
12. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
13. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
[TBL] [Abstract][Full Text] [Related]
14. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Yang B; Zhang H; Wang H
J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
[TBL] [Abstract][Full Text] [Related]
15. Investigating molecular dynamics-guided lead optimization of EGFR inhibitors.
Lavecchia MJ; Puig de la Bellacasa R; Borrell JI; Cavasotto CN
Bioorg Med Chem; 2016 Feb; 24(4):768-78. PubMed ID: 26810832
[TBL] [Abstract][Full Text] [Related]
16. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
Park J; McDonald JJ; Petter RC; Houk KN
J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
18. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
[TBL] [Abstract][Full Text] [Related]
20. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
